The medication used for recurrent H. Pylori infection entails the prescription and the administration of single regimen of a 20 mg of metronidazole-omeprazole and a 500 mg of clarithromycin that is intended to be consumed daily for a period of not more than ten days from the start of medication (ACG, 2017). Fundamentally, a single dose of regimen is supposed to eradicate a 90% chance of succumbing to the adverse effects of recurrent H. Pylori infection, and this means that the majority of patients who have been diagnosed with recurrent H. Pylori infection would register excellent patient compliance.
However, it is quite imperative to note that the metronidazole resistance has insignificant chances of eradicating the intensity of the regimen. Furthermore, in situations where patients' response is poor with regards to the treatment with metronidazole clarithromycin, it is recommended that the best treatment specification is bismuth-based triple therapy (Chey, Leontiadis, Howden & Moss, 2017). Besides, such a patient also needs a proton pump for a period of not less than 14 days. Given the medical history of the 46-year-old patient, it is recommended that the clinician conducts a meta-analysis of the organism in a bid to obtain antibiotic sensitivities that increases the chances of eradicated recurrent H. Pylori infection by 80% (Chey et al., 2017)
Delegate your assignment to our experts and they will do the rest.
The new therapy guidelines for pylori treatment entail the significance of eradicated recurrent H. Pylori infection as a step to fighting the phenomenon of ulcer disease. Besides, the new therapy guidelines affirm that the more a patient receives eradication therapy, there is an increased chance of a patient developing resistance to medication based on the prevalence of clarithromycin (Safavi, Sabourian & Foroumadi, 2016). Ultimately, the patient education regarding the case of recurrent H. Pylori infection calls for a conclusive understanding of antibiotic sensitivity testing as an affirmative platform for eradicating therapeutic complications with regards to the treatment of recurrent H. Pylori infection.
References
American Academy of Gastroenterology Clinical Guidelines (ACG). (2017). Management of Hpylori Guideline Link-. http://gi.org/wp-content/uploads/2017/02/ACGManagementofHpyloriGuideline2017.pdf
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: treatment of Helicobacter pylori infection. American Journal of Gastroenterology , 112 (2), 212-239.
Safavi, M., Sabourian, R., & Foroumadi, A. (2016). Treatment of Helicobacter pylori infection: Current and future insights. World journal of clinical cases , 4 (1), 5.
